Collaborative Fund Advisors LLC Buys New Stake in Johnson & Johnson $JNJ

Collaborative Fund Advisors LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, HoldingsChannel reports. The fund bought 4,427 shares of the company’s stock, valued at approximately $1,082,000.

Other institutional investors also recently made changes to their positions in the company. Greenberg Financial Group acquired a new position in Johnson & Johnson in the 4th quarter valued at $954,000. World Investment Advisors boosted its holdings in shares of Johnson & Johnson by 19.6% during the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after purchasing an additional 26,450 shares during the last quarter. Coldstream Capital Management Inc. grew its position in shares of Johnson & Johnson by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock valued at $17,738,000 after purchasing an additional 8,533 shares during the period. Benchmark Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $554,000. Finally, Sagespring Wealth Partners LLC lifted its position in Johnson & Johnson by 6.2% during the fourth quarter. Sagespring Wealth Partners LLC now owns 45,222 shares of the company’s stock worth $9,359,000 after buying an additional 2,660 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Guggenheim raised their target price on shares of Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Bank of America boosted their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Johnson Rice set a $270.00 price target on shares of Johnson & Johnson in a research note on Friday, June 26th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a report on Wednesday. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $257.74.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced FDA approval for its dual-energy THERMOCOOL SMARTTOUCH SF platform, a positive catalyst that could support growth in the company’s medtech business and improve investor confidence in its pipeline. Article Title
• Positive Sentiment: The stock had recently been pushing to record highs as analysts raised price targets and investors responded to a higher outlook and pre-earnings optimism, suggesting the long-term setup for JNJ remains constructive. Article Title
• Neutral Sentiment: Commentary this week also highlighted JNJ as a defensive healthcare name with steady cash flow, while other pieces focused on valuation, earnings expectations, and healthcare sector comparisons rather than new company-specific setbacks. Article Title
• Negative Sentiment: Despite the positive product news, some trading-focused coverage noted unusual put option activity after the recent run-up, indicating that a portion of the market is positioning for a possible pullback. Article Title
• Negative Sentiment: One market recap also described JNJ as declining more than the broader market, reinforcing the idea that the stock is pausing after a strong advance rather than reacting to a major fundamental problem. Article Title

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $263.52 on Thursday. The firm has a fifty day moving average of $235.85 and a 200-day moving average of $232.52. Johnson & Johnson has a 52-week low of $154.80 and a 52-week high of $269.43. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $634.34 billion, a P/E ratio of 30.46, a PEG ratio of 2.62 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the previous year, the business posted $2.77 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.